FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Quinidine Gluconate Injection
Status: Discontinuation
»Therapeutic Categories: Anti-Infective; Cardiovascular

Eli Lilly and Co. (Revised 12/01/2017)

Company Contact Information:

Presentation Posting Date Related Information
QUINIDINE GLUCONATE, 80 mg/1 mL,10 mL/vial Injectable (NDC 0002-1407-01) 12/01/2017 Discontinuation of the manufacture of the drug. The product distribution will continue until labeled expiry of March 2019. FDA and CDC are developing a strategy to ensure continued access to essential medicine for the treatment of severe malaria in the United States.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English